<code id='A0C9254283'></code><style id='A0C9254283'></style>

<acronym id='A0C9254283'></acronym>

<center id='A0C9254283'><center id='A0C9254283'><tfoot id='A0C9254283'></tfoot></center><abbr id='A0C9254283'><dir id='A0C9254283'><tfoot id='A0C9254283'></tfoot><noframes id='A0C9254283'>

<optgroup id='A0C9254283'><strike id='A0C9254283'><sup id='A0C9254283'></sup></strike><code id='A0C9254283'></code></optgroup>

<b id='A0C9254283'><label id='A0C9254283'><select id='A0C9254283'><dt id='A0C9254283'><span id='A0C9254283'></span></dt></select></label></b><u id='A0C9254283'></u>

~~<i id='A0C9254283'><strike id='A0C9254283'><tt id='A0C9254283'><pre id='A0C9254283'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：Wikipedia 2025-10-01 13:04:04 Page View：6983

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

advertisement

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： House looks to weaken Medicare negotiation
Next article： What does generative AI mean for health care? We asked experts

explore

United colonoscopy coverage change 'may cost lives,' doctors say

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

JasonBuenrostroinhisHarvardlab.CourtesyJohnD.andCatherineT.MacArthurFoundationTheyoungestofthisyear’

DIEP, the 'gold standard' of breast reconstruction, is under threat

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Results on Novartis prostate cancer therapy could expand its use

TheNovartisboothatESMO2023inMadrid.AndrewJoseph/STATMADRID—ResultspresentedMondaycouldexpandtheuseof

read more